Pfizer Inc. (NYSE:PFE)

The period under review demonstrates significant fluctuations in economic profit. Net operating profit after taxes (NOPAT) exhibited substantial growth from 2020 to 2022, followed by a considerable decline in 2023 and a partial recovery in 2024. Invested capital also showed volatility, decreasing in 2021 before increasing significantly in 2023 and then decreasing again in 2024. The cost of capital remained relatively stable, with a slight increase from 2020 to 2022 and a decrease in 2023, followed by a slight increase in 2024.

Economic Profit Trend

Economic profit began at a negative value in 2020, at -3,930 US$ millions. A strong positive trend followed, peaking at 19,589 US$ millions in 2022. However, 2023 saw a dramatic reversal, resulting in a loss of -15,026 US$ millions. The final year, 2024, showed a reduction in the loss, but remained negative at -4,910 US$ millions. This suggests a period of strong value creation followed by a period of value destruction, with a limited recovery in the most recent year.

NOPAT and Economic Profit Relationship

The movement of economic profit closely mirrors that of NOPAT. The substantial increase in NOPAT from 2020 to 2022 directly contributed to the growth in economic profit during the same period. Conversely, the significant decrease in NOPAT in 2023 was the primary driver of the large negative economic profit observed that year. The partial recovery in NOPAT in 2024 led to a lessened negative economic profit.

Invested Capital and Cost of Capital Influence

While NOPAT is a primary driver, changes in invested capital and cost of capital also play a role. The increase in invested capital in 2023, coupled with the decrease in cost of capital, did not fully offset the substantial decline in NOPAT, resulting in a significant negative economic profit. The decrease in invested capital in 2024, alongside a slight increase in cost of capital, contributed to a less negative economic profit compared to the previous year.

Overall, the period was characterized by considerable volatility in economic profit, largely driven by fluctuations in NOPAT. While the company demonstrated the ability to generate substantial economic profit, it also experienced a period of significant value destruction. The interplay between NOPAT, invested capital, and cost of capital is evident in the observed trends.

The financial data reveals notable fluctuations in profitability measures over the five-year period under review. Both net income attributable to common shareholders and net operating profit after taxes (NOPAT) exhibit significant variability, indicating shifts in operational efficiency and overall financial performance.

Net Income Attributable to Pfizer Inc. Common Shareholders

The net income increased substantially from 9,616 million USD in 2020 to a peak of 31,372 million USD in 2022. This growth signals a period of heightened profitability. However, the figure declined sharply to 2,119 million USD in 2023, representing a significant downturn. The net income rebounded in 2024 to 8,031 million USD, yet remained well below the peak levels observed in 2021 and 2022.

Net Operating Profit After Taxes (NOPAT)

The NOPAT followed a similar trajectory as net income. It rose from 6,095 million USD in 2020 to a maximum of 31,018 million USD in 2022, demonstrating improved operational performance and effective tax management during this period. In 2023, NOPAT turned negative to -1,277 million USD, reflecting operational challenges and possibly extraordinary items impacting profitability. The measure recovered moderately in 2024, reaching 7,374 million USD, yet still significantly lower compared to the peak years.

Overall, the data indicates a strong growth trend in profitability through 2022, followed by a pronounced decline in 2023, and a partial recovery in 2024. The volatile pattern suggests the presence of external or internal factors causing fluctuations in earnings and operating profitability, which could merit further investigation to understand the underlying drivers and sustainability of recent earnings levels.

Provision (benefit) for taxes on income

The provision for taxes on income demonstrated significant volatility over the observed periods. Initially, it increased notably from 477 million USD in 2020 to a peak of 3,328 million USD in 2022. Subsequently, it shifted to a negative value, indicating a tax benefit, with -1,115 million USD recorded in 2023, followed by a marginal negative provision of -28 million USD in 2024. This pattern suggests a possible influence of tax credits, adjustments, or one-time events impacting the effective tax expense.

Cash operating taxes

Cash operating taxes exhibited a rising trend from 2,090 million USD in 2020 to a peak of 7,967 million USD in 2022. After reaching this high point, there was a pronounced decline to 2,113 million USD in 2023. The figure modestly increased again to 2,426 million USD in 2024. This fluctuation indicates variability in the company’s cash tax obligations, potentially reflecting changes in taxable income, tax planning strategies, or timing differences in tax payments.

The data reveals significant fluctuations across the reported financial items over the five-year period from 2020 to 2024.

Total reported debt & leases

This figure remained relatively stable between 2020 and 2022, with values around 41,000 million US dollars. However, it increased substantially in 2023 to over 75,000 million US dollars, representing almost a doubling compared to the previous year. In 2024, there was a decrease to approximately 67,000 million US dollars, though this figure remained markedly higher than the levels seen from 2020 to 2022.

Total Pfizer Inc. shareholders’ equity

Shareholders’ equity exhibited a generally increasing trend from 63,238 million US dollars in 2020, rising steadily to a peak of 95,661 million US dollars in 2022. Following this apex, the equity declined moderately in the succeeding two years, reaching 88,203 million US dollars by the end of 2024. Despite the decrease post-2022, the equity values in 2023 and 2024 remained higher than the initial 2020 level.

Invested capital

Invested capital presents a more volatile trend. Starting at 103,898 million US dollars in 2020, it decreased to 87,670 million US dollars in 2021, indicating a contraction. This was followed by a substantial increase in 2022 to 110,746 million US dollars and an even sharper rise in 2023 to 154,882 million US dollars. By 2024, invested capital receded to 135,777 million US dollars but remained significantly above the 2020 level.

Overall, the data highlights a phase of increased leverage in 2023, as reflected by the sharp rise in total reported debt and leases, coupled with a significant buildup of invested capital during the same period. Shareholders’ equity expanded robustly through 2022, peaking before experiencing moderate declines, suggesting possible distribution of earnings or adjustments in retained earnings. The trends indicate dynamic financial management actions influencing capital structure and investment intensity, especially from 2022 through 2024.

The economic spread ratio exhibited significant fluctuations over the five-year period. Initially negative in 2020, it demonstrated substantial improvement in subsequent years before declining again. Economic profit followed a similar volatile pattern, moving from a substantial loss to significant gains and then back to losses.

Economic Spread Ratio - Overall Trend

The economic spread ratio began at -3.78% in 2020, indicating that the company’s return on invested capital was less than its cost of capital. A marked positive shift occurred in 2021, with the ratio increasing to 10.87%, suggesting the company generated returns exceeding its cost of capital. This positive trend continued into 2022, reaching a peak of 17.69%. However, the ratio experienced a sharp decline in 2023, falling to -9.70%, and continued to decrease, albeit at a slower pace, to -3.62% in 2024. This suggests a weakening ability to generate returns above the cost of capital in the latter part of the period.

Economic Profit and Invested Capital Relationship

Economic profit and invested capital moved in contrasting directions at times. While economic profit was negative in 2020 and 2023-2024, invested capital generally increased over the period, with a notable rise in 2023. The decline in the economic spread ratio in 2023 and 2024, despite a substantial increase in invested capital in 2023, suggests that the returns generated from the increased capital were insufficient to offset the cost of that capital. The decrease in invested capital in 2024 may have partially mitigated the negative economic spread, but did not return it to positive territory.

The period demonstrates a cyclical pattern. The initial negative economic spread in 2020 was followed by two years of strong performance, then a return to negative economic profit and spread in the final two years. This suggests potential sensitivity to external factors or internal strategic shifts impacting profitability relative to capital employed.

The economic profit margin exhibited significant fluctuations over the five-year period. Initial observations reveal a substantial shift from negative economic profit in 2020 to positive values in 2021 and 2022, followed by a return to negative economic profit in 2023 and 2024.

Economic Profit Margin Trend

In 2020, the economic profit margin was -9.21%, indicating that the company’s economic profit was negative relative to its revenues. A dramatic improvement occurred in 2021, with the margin rising to 11.60%. This positive trend continued into 2022, reaching a peak of 19.36%, suggesting a period of strong economic performance. However, the margin experienced a sharp decline in 2023, falling to -25.23%, representing the lowest value within the observed timeframe. The margin partially recovered in 2024, increasing to -7.72%, though it remained negative.

Revenues demonstrated an overall increasing trend, with a notable surge between 2020 and 2022. Revenues increased from US$42,678 million in 2020 to US$82,145 million in 2021, and further to US$101,175 million in 2022. A significant decrease was observed in 2023, with revenues dropping to US$59,553 million. Revenues experienced a modest increase in 2024, reaching US$63,627 million, but remained below the 2022 level.

Relationship between Revenues and Economic Profit Margin

The period of highest revenue growth (2020-2022) coincided with the period of positive and increasing economic profit margins. However, the substantial revenue decline in 2023 was accompanied by a significant drop in the economic profit margin to a negative value. The partial revenue recovery in 2024 did not fully translate into an improved economic profit margin, indicating that factors beyond revenue levels were influencing economic profitability. This suggests that cost of capital and operational efficiency play a crucial role in determining economic profit.

The volatility in economic profit, as reflected in the economic profit margin, suggests potential sensitivity to external factors or internal strategic shifts. Further investigation into the underlying drivers of these fluctuations would be necessary to fully understand the company’s economic performance.